Aims: Spontaneous nephrocutaneous fistula (NCF) is a rare and severe condition. The aim of this study was to update the data of the literature about this disease and, reporting and considering also our experience in 1 case of NCF, to make a new clinical algorithm. Methods: This study was done with a review of all the literature and a comparison with our experience. Results: The characteristic sign of spontaneous NCF is a flank sinus discharging material. Physical examination and computed tomography usually lead to the diagnosis. The main predisposing factors are renal stones/staghorn calculi, xanthogranulomatous pyelonephritis and renal tuberculosis. In the vast majority of the cases kidneys are poorly functioning or nonfunctioning. Surgical approach is the common management and usually consists of open nephrectomy. We create a clinical management algorithm obtained by a review of the literature and our experience with spontaneous NCF. Conclusions: Spontaneous NCF represents a very serious renal disease leading to loss of the kidney in the vast majority of cases. We propose a revised and user-friendly clinical diagnostic-therapeutic algorithm for spontaneous NCF based on the worldwide literature.

Keywords:
Spontaneous nephrocutaneous fistula, Poorly functioning/nonfunctioning kidney, Renal stones, Xanthogranulomatous pyelonephritis, Open nephrectomy
1.
Motiwala HG: Spontaneous nephrocutaneous fistula: a rare complication of reflux nephropathy. Int Urol Nephrol 1997;29:411-414.
2.
Das S, Ching V: Nephrocutaneous sinus: a case report. J Urol 1979;122:232.
3.
Singer AJ: Spontaneous nephrocutaneous fistula. Urology 2002;60:1109-1110.
4.
Pankaj NM, Hemendra NS: Nephrocutaneous fistula through percutaneous nephrolitotomy scar: rare presentation of genitourinary tuberculosis. Urology 2005;66:655-656.
5.
Qureshi MA: Spontaneous nephrocutaneous fistula in tuberculosis pyelonephritis. J Coll Physicians Surg Pak 2007;17:367-368.
6.
Biyani CS, Torella F, Cornford PA, et al: Xanthogranulomatous pyelonephritis with bilateral nephrocutaneous fistulae. Urol Int 1997;59:46-47.
7.
Khallouk A, Tazi MF, Elfassi MJ, et al: Chronic spontaneous nephrocutaneous fistula associated with renal replacement lipomatosis. Rev Urol 2010;12:e190-e192.
8.
Sherman SC, Limkakeng A: Xanthogranulomatous pyelonephritis with a nephrocutaneous fistula. J Emerg Med 2005;29:337-338.
9.
Bryniak SR: Primary spontaneous renocutaneous fistula. Urology 1983;21:516-517.
10.
Karfopoulos AS, Murray W, Stone FJ: Nephrocutaneous fistula. J Med Soc NJ 1981;78:379-380.
11.
Kijvikai K, Dissaranan C, Chalermsanyakorn P, et al: Hand assisted laparoscopic nephrectomy for xanthogranulomatous pyelonephritis with nephrocutaneous fistula after failed flank exploration. Surg Laparosc Endosc Percutan Tech 2006;16:263-266.
12.
Colls P, Guyon P, Chiche L, et al: Renocutaneous fistula: report of a chronic inguinal fistula. Ann Urol 2000;34:222-227.
13.
Ansari MS, Singh I, Dogra PN: Spontaneous nephrocutaneous fistula: 2 unusual reports with review of literature. Int Urol Nephrol 2004;36:239-243.
14.
Grabe M, Bjerklund-Johansen TE, Botto H, et al: Guidelines on Urological Infections. European Association of Urology, 2013, 4.4.2, p 29.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.